Audit: QRS - Common Hawthorn for Health & Longevity

Audit conducted on 11/06/2026 03:12 using AI4L + evidence-mcp / Opus 5.5

Iterations

Summary

Items Count
Total 97
Passed 87
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All lede, Protocol, Time to effect, gate, tier and Monitoring content traces to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions & Contraindications, Monitoring Protocol).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Lede keeps “remains uncertain”, “appears well tolerated”, “inconsistent”; NT-proBNP target keeps “No established target”.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening or softening found; contraindication qualifiers (≤35%, 2 weeks, age limits) kept as in ER.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications, documented and theoretical interactions, benefits and risks sit in the ER’s own categories and tiers.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 Only WS 1442, EMA and Korodin appear; all are in the ER for the same facts. No PMIDs, NCT IDs or study names.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is expert, accessible, objective, and data-driven 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses the reader directly — it presents evidence, not guidance 🟢  
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms (NT-proBNP, PDE5 inhibitors, NSAIDs, Vitamin K antagonists) are carried verbatim from ER labels; lede is in plain language.
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.10 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.11 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Lede notes the evidence comes mostly from heart patients and benefit for others remains uncertain.
2.13 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” wording.
2.14 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢  

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings, gate headings, tier labels and column headers match the template.
3.2 Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name 🟢 All template variables present; marker_# and qualitative_item_# expanded to numbered names per 14.2/15.2.
3.3 Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well 🟢 Source diff against template shows changes only inside data-qrs-var spans, display:none on empty tiers, and metadata fields.

4. Formatting

# Description Result Comments
4.1 An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. 🟢 Empty High benefit and High/Medium risk tiers hidden; no empty-state phrasing.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels, contraindication and interaction labels use the ER’s bold labels.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Interaction example lists trimmed only, at least one example kept per group, ER wording retained.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators.
4.5 The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. 🟢 No trailing dash clauses, optional glosses, untrimmed example lists or repetitions found.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: common_hawthorn_2026-1105-2330_Opus_ER.md
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.10.25 matches QRS.md.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-1106-0257
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name 🟢 Opus
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model 🟢 Opus 5.5
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢  
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 11/06/2026
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Opus 5.5
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens with “Hawthorn, a shrub, yields leaf-and-flower extracts sold as heart-tonic supplements”.
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.3 [at_a_glance] is no longer than 70 words 🟢 70 words (script count).
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each fact maps to a distinct ER Conclusion passage.
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢  
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 Trials described generically (“most careful independent trial”, “the largest”).
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All six ER “Populations who should avoid” items present.
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Dash-appended severity words (“— Contraindicated”, “— Avoid”) stripped; no rationale or citations.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Age limits, 2-week review window and ≤35% threshold preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation in contraindications.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Section populated; ER names populations to avoid.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found 🟢 D-Camphor and Vitamin K antagonists listed; digoxin, heart failure regimens and diabetes drug entries (no interaction found) correctly excluded.
9.3 [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label 🟢 All seven ER theoretical interactions listed.
9.4 The ER placeholder “None identified” is never an item: it means that group is empty 🟢  
9.5 Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause 🟢  
9.6 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
9.7 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists kept, trimmed.
9.8 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation in interactions.
9.9 If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. N/A ER theoretical group is not empty.
9.10 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢  
9.11 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. N/A Section not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Therapeutic Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from that section 🟢 Heart failure extract, blood pressure regimens and traditional EMA regimens.
10.3 If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. N/A ER has at least three actionable aspects.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢  
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Heart failure workload and blood pressure (both Medium benefits, ER order) precede the general herbalist expectation.
11.3 If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. N/A ER gives three time-to-effect aspects.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
12.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 Empty High tier hidden with display:none.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
13.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 Empty High and Medium tiers hidden with display:none.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
14.2 All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names 🟢 Blood pressure, resting heart rate, serum digoxin, NT-proBNP, ejection fraction and body weight listed as rows 1–6.
14.3 [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” 🟢 Targets as in ER; ejection fraction and body weight written “Not specified in the ER”.
14.4 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. 🟢  
14.5 If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template N/A ER names measurable biomarkers.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
15.2 All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … 🟢 All six ER qualitative markers listed as items 1–6.
15.3 If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template N/A ER names qualitative markers.

Issues 11/06/2026 03:12

Pass rate 100.00%. No issues found.

Issues 11/06/2026 03:10

  1. 4.5 — Untrimmed interaction example lists: The theoretical interactions at lines 572 (“nitroglycerin, isosorbide mononitrate; sildenafil, tadalafil”), 574 (“amiodarone, sotalol, flecainide”), 575 (“lily of the valley, foxglove, oleander”) and 576 (“hibiscus, garlic, coenzyme Q10”) carry the ER’s full example lists, and line 573 still lists four examples.

Fixes 11/06/2026 03:10

  1. 4.5 — Trimmed interaction example lists: Shortened the theoretical-interaction example lists to one example per drug class or two for herbs and supplements (e.g., “nitroglycerin, isosorbide mononitrate; sildenafil, tadalafil” to “nitroglycerin; sildenafil”; dropped naproxen, sotalol, flecainide, lily of the valley and coenzyme Q10).

Issues 11/06/2026 03:07

  1. 1.1 / 1.3 — Blood pressure claim generalized: The at-a-glance at line 439 states “a modest, inconsistent fall in high blood pressure”, while the ER Conclusion limits it to “a modest fall in the upper reading” (diastolic not significant per the Medium benefit), strengthening the claim.

Fixes 11/06/2026 03:07

  1. 1.1 / 1.3 — Blood pressure claim generalized: Changed the at-a-glance from “a modest, inconsistent fall in high blood pressure” to “a modest, inconsistent fall in raised upper blood-pressure readings”; shortened “have contained” to “contained” to stay within 70 words.

Issues 11/06/2026 03:04

  1. 8.5 — Time-window qualifier dropped: The “Undiagnosed cardiac symptoms” contraindication at line 551 omits the ER qualifier “with medical review if symptoms persist beyond 2 weeks”.

Fixes 11/06/2026 03:04

  1. 8.5 — Time-window qualifier restored: Changed the contraindication to “Undiagnosed cardiac symptoms (until serious heart conditions are excluded by a doctor; medical review if symptoms persist beyond 2 weeks)”.

Issues 11/06/2026 03:00

  1. 1.2 / 1.3 — Blood pressure hedge dropped: The lede at line 439 says “pooled trials point to a modest fall in the upper reading”, dropping the ER Conclusion’s “small” and “with inconsistent results”.
  2. 2.12 — Audience framing missing: The lede at line 439 omits the ER Conclusion’s point that most evidence comes from people sicker than health-focused adults without heart disease, for whom benefit remains uncertain.
  3. 4.5 — Untrimmed repetitive example list: The theoretical antiplatelet item at line 573 lists six examples and repeats “aspirin”, already named in the label “including over-the-counter aspirin and NSAIDs”.
  4. 14.2 — Missing measurable markers: The ER Monitoring section names baseline ejection fraction and weekly body weight for heart failure (ER lines 393, 395); neither has a Monitoring table row.

Fixes 11/06/2026 03:00

  1. 1.2 / 1.3 — Blood pressure hedge restored: Changed the lede’s “pooled trials point to a modest fall in the upper reading” to “Pooled small trials point to a modest, inconsistent fall in high blood pressure”, carrying the ER’s “small” and “inconsistent” qualifiers.
  2. 2.12 — Audience framing added: Added to the lede that hawthorn was “mostly studied in heart patients; benefit for others remains uncertain”, and tightened other lede clauses to stay at 70 words.
  3. 4.5 — Example list trimmed: Shortened the theoretical antiplatelet item’s examples from “(clopidogrel, apixaban, rivaroxaban; aspirin, ibuprofen, naproxen)” to “(clopidogrel, apixaban; ibuprofen, naproxen)”, removing the repeated “aspirin”.
  4. 14.2 — Missing markers added: Added Monitoring rows marker_5 “Ejection fraction (heart failure only)” and marker_6 “Body weight (heart failure only)”, both with target “Not specified in the ER”.